Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of REGN2477 and REGN1033 in Healthy Volunteers
NCT02943239Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of garetosmab and trevogrumab in Sarcopenia and muscle atrophy (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment-emergent adverse events up to 40 weeks. Started Dec 2016; status: completed.
02
Drugs
garetosmabtrevogrumab
03
Conditions
Sarcopeniamuscle atrophy
Beyond the preview
Go deeper on NCT02943239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943239.